CClinicalTrials.gg
RecruitingNCT04467502VIRET-GADUpdated May 14, 2026

Virtual Reality Exposure Therapy for Gambling Disorder

An interventional study of cognitive-behavioral therapy for gambling disorder and imaginal exposure therapy focus on gambling cues in Gambling Disorder, sponsored by University Hospital, Lille. Recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Gambling disorder (GD) is recognized as an addictive disorder in the DSM-5. Craving is a core phenomenon in addiction that can lead to relapse in problem gambling for pathological gamblers. Exposure Therapy (ET) focuses on craving in addiction treatment. ET in Cognitive-Behavioral Therapy (CBT) is based on classical conditioning that addresses the association between contextual cues and the craving response. ET helps the patient to reduce craving when faced with cues triggering craving. ET includes in vivo exposure and imaginal exposure. The literature recommends being as close as possible to the context of addiction to facilitate the extinction of craving but in vivo ET is complicated to perform. For GD, in outpatient consultation, bringing a patient to a casino presents obstacles (e.g., time, human and financial cost, agreement with casino for therapy).

The study will be to assess the effectiveness of Virtual Reality Exposure Therapy (VRET) in a virtual gambling environment. Various trials show that VRET is no more or less effective than classical ET in CBT but has other advantages for motivation to treatment. This research aims to compare efficacy between CBT with VRET and CBT with imaginal exposure for treatment of GD in a multicenter, randomized, controlled, non-inferiority clinical trial.

Read the detailed description

Main aim:

Show, within patients seeking care for GD, that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction at the end of 12 treatment sessions.

Secondary objectives:

  1. Show that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction during the first 12 months post-treatment.
  2. Compare the effect of the two therapeutic strategies on GD symptoms (measured by complementary assessments to that used in the main aim), at the end of treatment and during the first 12 months post-treatment.
  3. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on gambling behavior, craving, and gambling-related cognitions at the end of treatment and during the first 12 months post-treatment.
  4. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on the evolution of anxiety and depressive symptoms at the end of treatment and during the first 12 months post-treatment.
  5. Compare the quality of the two therapeutic strategies at the end of treatment.
02

Conditions studied

  • Gambling Disorder

Browse trials for

Keywords

  • Exposure therapy
  • virtual reality
  • cognitive behavioral therapy
  • pathological gambling
  • CBT
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Seek treatment for GD within one of health care facilities participating in the research (first request for treatment and not patients already receiving treatment for gambling disorder in the care center).
  • Meet a current diagnosis of gambling disorder according to DSM-5 criteria and with a South Oaks Gambling Screen (SOGS) score ≥ 5
  • Meet a casino gambling behavior with a casino gambling frequency ≥ 1 time every two months during the last 12 months
  • Have a sufficient understanding of French for therapy
  • Beneficiary of the French social security system
  • Give an informed consent to participate
  • Willing to comply with all study procedures and duration

Exclusion criteria

Exclusion Criteria:

  • Visual disturbance making impossible the use of virtual reality equipment (e.g. advanced retinal degeneration, central scotoma, age-related macular degeneration)
  • Pregnant woman
  • Minor or adult under guardianship, conservatorship, under judicial protection, persons deprived of their liberty
  • Balance disorder (e.g. cerebellar disorder, inner ear disorder)
  • Photosensitive epilepsy
  • Refusal to participate
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    CBT with VRET

    Other: cognitive-behavioral therapy for gambling disorder · Other: virtual reality exposure therapy focus on gambling cues

  • Active comparator
    CBT with imaginal ET

    Other: cognitive-behavioral therapy for gambling disorder · Other: imaginal exposure therapy focus on gambling cues

Interventions

  • Othercognitive-behavioral therapy for gambling disorder

    6 sessions of cognitive-behavioral therapy for gambling disorder

  • Otherimaginal exposure therapy focus on gambling cues

    6 sessions of imaginal exposure therapy focus on gambling cues

  • Othervirtual reality exposure therapy focus on gambling cues

    6 sessions of virtual reality exposure therapy focus on gambling cues

05

What researchers measure

Primary outcomes

  1. Change in South Oaks Gambling Screen (SOGS) between baseline and end of treatment (12 sessions, 6 months)

    The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.

    Time frame: at the end of treatment (an average of 6 months)

Secondary outcomes

  1. Change in South Oaks Gambling Screen (SOGS) between baseline and follow-up at 3, 6 and 12 months after the end of treatment

    The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.

    Time frame: at baseline, and through study completion, an average of 18 months

  2. Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: number of DSM-5 criteria for GD

    Nine criteria for gambling disorder are described in DSM-5. The endorsement of 4-5 criteria means the presence of a mild gambling disorder, 6-7 criteria a moderate gambling disorder and 8-9 criteria a severe gambling disorder. The score ranges from 0 to 9 criteria.

    Time frame: at baseline, and through study completion, an average of 18 months

  3. Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: Problem Gambling Severity Index (PGSI)

    The PGSI consists of nine items to assess level of risk for problem gambling. Cut-off scores are 1-2 for low-risk gamblers, 3-7 for moderate-risk gamblers and 8 or more for problem-gamblers. Non-problem gamblers correspond to 0. The score ranges from 0 to 27.

    Time frame: at baseline, and through study completion, an average of 18 months

  4. Change in gambling behavior assessed by gambling frequency during the last month

    Time frame: at baseline, and through study completion, an average of 18 months

  5. Change in gambling behavior assessed by amount of money spent in gambling during the last month

    Time frame: at baseline, and through study completion, an average of 18 months

  6. Change in gambling behavior assessed by time spent gambling during the last month

    Time frame: at baseline, and through study completion, an average of 18 months

  7. Change in frequency subscale of gambling Craving Experience Questionnaire (g-CEQ)

    The frequency subscale of gambling Craving Experience Questionnaire assesses the frequency of craving for gambling during the last week. This questionnaire consists of nine items. A high score means a high frequency of craving during the last week. The score ranges from 0 to 90.

    Time frame: at baseline, and through study completion, an average of 18 months

  8. Change in craving reactivity to gambling cues

    Time frame: at baseline, and through study completion, an average of 18 months

  9. Number of craving episodes using daily craving assessed by participants

    Time frame: up to 6 months during the treatment

  10. Cumulative duration of craving episodes using daily craving assessed by participants

    Time frame: up to 6 months during the treatment

  11. Change in gambling-related cognitions assessed by Gambling-Related Cognitions Scale (GRCS)

    The French version of the Gambling-Related Cognitions Scale consists of 23 items to assess various cognitions related to gambling. A high score means that gambling-related cognitions are typical cognitions of problem gamblers. The score ranges from 23 to 161.

    Time frame: at baseline, and through study completion, an average of 18 months

  12. Change in depressive symptoms assessed by Beck Depression Inventory short-form (BDI-SF)

    Beck Depression Inventory short-form consists of 13 items to assess depressive symptoms. A high score means a high level of depressive symptoms. The score ranges from 0 to 39.

    Time frame: at baseline, and through study completion, an average of 18 months

  13. Change in anxiety symptoms assessed by State-Trait Anxiety Inventory (STAI)

    State-Trait Anxiety Inventory consists of 20 items to assess state-anxiety and 20 items to assess trait-anxiety. A high score means a high level of anxiety symptoms. The score ranges from 20 to 80 both for state-anxiety and trait-anxiety.

    Time frame: at baseline, and through study completion, an average of 18 months

  14. Rate of patients who attended the 12 sessions (6 months)

    Quality of the two therapeutic strategies

    Time frame: up to 6 months during the treatment

06

Study locations

1 of 10 sites recruiting
  • CHU Amiens-Picardie
    Amiens, France
    • Alain DERVAUX, MD,PhD · Principal investigator
    Not yet recruiting
  • CH Boulogne sur mer CSAPA
    Boulogne-sur-Mer, France
    • Fréderic TEISSIERE, MD · Principal investigator
    Not yet recruiting
  • CHU de Caen
    Caen, France
    • Nicolas CABE, MD · Principal investigator
    Not yet recruiting
  • Hôpital Fontan, CHU lille
    Lille, 59000, France
    • Olivier COTTENCIN, MD,PhD · Principal investigator
    Not yet recruiting
  • Assoriation Cédragir Lomme CSAPA
    Lomme, France
    • Stéphanie Lienard · Sub investigator
    Not yet recruiting
  • CH de l'arrondissement de Montreuil / CSAPA
    Montreuil-sur-Mer, France
    • Mathieu LAWNICZAK · Sub investigator
    Not yet recruiting
  • CHU Rouen
    Rouen, France
    • Olivier GUILLIN, MD, PhD · Principal investigator
    Not yet recruiting
  • CH de Saint Amand les Eaux
    Saint-Amand-les-Eaux, France
    • Charles LESCUT, MD · Principal investigator
    Not yet recruiting
  • CH Seclin Carvin CSAPA
    Seclin, France
    • Pierre TAQUET, PhD · Principal investigator
    Recruiting
  • Association GREID ValenciennesCSAPA
    Valenciennes, France
    • Ines Roux · Sub investigator
    Not yet recruiting
07

Registry details

Key details

Study ID
NCT04467502
Lead sponsor
University Hospital, Lille
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Jul 12, 2023
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 14, 2026

Study contacts

Pierre TAQUET, PhD
Contact
pierre.taquet@chru-lille.fr
0320445838 ext. +33
Pierre TAQUET, PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion